These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9540056)

  • 1. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
    Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
    J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence.
    Hakin-Smith V; Battersby RD; Maltby EL; Timperley WR; Royds JA
    Neuropathol Appl Neurobiol; 2001 Feb; 27(1):40-9. PubMed ID: 11299001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 overexpression and proliferative potential in malignant meningiomas.
    Nagashima G; Aoyagi M; Yamamoto M; Yamamoto S; Wakimoto H; Ohno K; Yamamoto K; Hirakawa K
    Acta Neurochir (Wien); 1999; 141(1):53-61; discussion 60-1. PubMed ID: 10071687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
    Miyagami M; Kanou T; Nakamura S
    No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of mdm2 and p53 and association with progesterone receptor expression in benign meningiomas.
    Das A; Tan WL; Teo J; Smith DR
    Neuropathology; 2002 Sep; 22(3):194-9. PubMed ID: 12416559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological analyses of early recurrence and malignant transformation in meningiomas.
    Arai H; Beppu T; Wada T; Yoshida Y; Kubo Y; Suzuki M; Ogawa A
    Brain Tumor Pathol; 1998; 15(1):37-40. PubMed ID: 9879462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
    Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
    Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Ki-67 and p53 in meningiomas.
    Pavelin S; Becic K; Forempoher G; Mrklic I; Pogorelic Z; Titlic M; Andelinovic S
    Neoplasma; 2013; 60(5):480-5. PubMed ID: 23790165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas.
    Matsuno A; Nagashima T; Matsuura R; Tanaka H; Hirakawa M; Murakami M; Tamura A; Kirino T
    Am J Clin Pathol; 1996 Dec; 106(6):776-81. PubMed ID: 8980354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation.
    Amatya VJ; Takeshima Y; Inai K
    Mod Pathol; 2004 Jun; 17(6):705-10. PubMed ID: 15073599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.
    Pykett MJ; Landers J; George DL
    J Neurooncol; 1997 Mar; 32(1):39-44. PubMed ID: 9049861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.